| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2004;43:483.)
© 2004 American Heart Association, Inc.
Scientific Contribution |
From the Division of Hypertension, Department of Internal Medicine (S.T.T.), Division of Biostatistics, Department of Health Sciences Research (M.D.A.), and Department of Diagnostic Radiology (C.R.J.), Mayo Clinic and Foundation, Rochester, Minn; Department of Medicine (T.H.M.), University of Mississippi, Jackson; and Human Genetics Center and Institute of Molecular Medicine (M.F., E.B.), University of Texas-Houston Health Science Center, Houston.
Correspondence to Dr Stephen T. Turner, Division of Hypertension, Mayo Clinic, 200 First Street SW, Rochester MN 55905. E-mail turner.stephen{at}mayo.edu
| Abstract |
|---|
|
|
|---|
Key Words: blood pressure hypertension, genetic genetics brain ischemia
| Introduction |
|---|
|
|
|---|
Most target organ damage from hypertension is caused by ischemia, which results from obstructive atherosclerosis that can acutely interrupt blood flow or from arteriolosclerosis that chronically impairs perfusion within target organs. Family studies have established that atherosclerosis, and each of its major biological risk factors, has a genetic basis.4 In contrast, studies to document a familial or genetic predisposition to arteriolosclerosis are almost nonexistent. Given some overlap in the risk factors for atherosclerosis and arteriolosclerosis (eg, hypertension), a shared genetic predisposition may be assumed; however, the processes are sufficiently distinct anatomically, histologically, and clinically to suggest that some of the causative factors may differ.5
Genetic influences on measures of brain morphology and function have been reported, including ventricular enlargement in response to aging.6,7 To our knowledge, all such studies involving noninvasive imaging of the brain used small samples of twins, which may not be representative of the general population. The heritability of leukoaraiosis estimated in 74 monozygotic and 71 dizygotic male twins who were 68 to 79 years old at MRI8 was 0.71, which is surprisingly high for a condition that develops so late in life. Therefore, our objective was to estimate the heritability of leukoaraiosis in a larger sample that included women and did not rely on twins. To accomplish this, we sampled an established cohort of siblings participating in a study to identify and characterize genetic determinants of hypertension and associated target organ complications.
| Materials and Methods |
|---|
|
|
|---|
Study Visits
Blood pressure measurements were made with random zero sphygmomanometers and cuffs appropriate for arm size. Three readings were taken from the right arm after the participant rested in the sitting position for at least 5 minutes; the last 2 readings were averaged for the analyses. Blood was drawn after an overnight fast of at least 8 hours. Serum creatinine, glucose, total cholesterol, triglycerides, and HDL cholesterol were measured by standard enzymatic methods. Each prescription medication recorded at the study visit was assigned a code based on mechanism of action. The diagnosis of hypertension was confirmed if a previous diagnosis of hypertension and use of prescription antihypertensive medication were reported, or if the average systolic or diastolic blood pressure was
140 mm Hg or
90 mm Hg, respectively. Diabetes was diagnosed if the subject reported treatment with insulin or oral hypoglycemic agents, or if the serum glucose concentration (fasting) was
126 mg/dL.
Brain MRI and Determination of Leukoaraiosis Volume
All scans were performed on identically equipped Signa 1.5 Tesla MRI scanners (GE Medical Systems, Waukesha, Wis) under the supervision of Mayo Clinic neuroradiologists. Symmetric head positioning with respect to orthogonal axes was verified by a series of short scout scans. Total intracranial volume (head size) was measured from T1-weighted sagittal images, with each set consisting of 192 contiguous 5-mm-thick slices with no interslice gap that were obtained with the following sequence: repetition time=500 milliseconds, echo time=20 milliseconds, repetitions=2, time=2.5 minutes, field of view=24 cm.10 Brain and leukoaraiosis volumes were determined from axial fluid-attenuated inversion recovery images, with each set consisting of 192 contiguous 3-mm interleaved slices with no interslice gap obtained with the following sequence: echo time=144.8 ms, inversion time=2600 ms, repetition time=11 000 ms, bandwidth=±32 kHz, echo train length=22, time=8 minutes, field of view=24 cm, matrix=256x192.11 A fluid-attenuated inversion recovery image is a T2-weighted image with the signal of cerebrospinal fluid nulled, such that brain pathology appears as the brightest intracranial tissue. Interactive image processing steps were performed by a research associate who had no knowledge of the subjects personal or medical histories or biological relationships. A fully automated algorithm was used to segment each slice of the edited multislice fluid-attenuated inversion recovery sequence into voxels assigned to 1 of 3 categories: brain, cerebrospinal fluid, or leukoaraiosis. The mean absolute error of this method is 1.4% for brain volume and 6.6% for leukoaraiosis volume, and the mean testretest coefficient of variation is 0.3% for brain volume and 1.4% for leukoaraiosis volume.12
Statistical Analyses
Descriptive statistics included means and SD for quantitative measures and percentages for categorical traits. Before estimating regression relationships between traits or heritabilities, skewed distributions were normalized by logarithm transformation.13 Covariates predictive of interindividual differences in leukoaraiosis volume were identified by use of regression tree-based recursive partitioning methods.14 A generalized estimating equations approach, assuming an identity link and allowing for correlation within sibships, was used to estimate relationships between risk factors and leukoaraiosis volume.15 Variance components methods were used to estimate the heritability of leukoaraiosis volume by fitting a statistical model that incorporates fixed effects for measured covariates and variance components for genetic effects16 By modeling the level of a quantitative trait, y, for the ith individual as yi=µ+
ßjXij+gi+ei, where µ is the trait mean, Xij is the jth covariate, and ßj is its regression coefficient, total variation in a trait is partitioned into components caused by the covariates (
ßjXij), additive genetic factors (gi), and environmental effects (ei) that may include nonadditive genetic effects, measurement error, and true random error. The effects of gi and ei are assumed to be uncorrelated and normally distributed with means of zero and variances
g2 and
e2. Maximum likelihood methods were used to simultaneously estimate the mean and variances as well as the covariate and genetic effects. Heritability was defined as the proportion of variance in a quantitative measure of leukoaraiosis volume explained by additive genetic factors relative to the total phenotypic variance (before adjustment for covariates) or to the residual phenotypic variance after adjustment for covariates. Heritability was estimated for the logarithm-transformed measure of leukoaraiosis volume before and after adjustments for the identified covariates. Statistical significance was assessed by comparing twice the difference in natural logarithm likelihoods between a model with genetic effects estimated and a model with these effects constrained to zero. Test statistics were considered statistically significant at P=0.05.
Descriptive statistics and regression relationships were calculated using SAS (SAS Institute, Cary, NC). Data transformations and tree-based recursive partitioning were performed using S-PLUS (Insightful Corporation, Seattle, Wash). Heritabilities were estimated using the Sequential Oligogenic Linkage Analysis Routines (SOLAR) program.17
| Results |
|---|
|
|
|---|
2 hypertensive members, 79.1% of subjects had hypertension and 74% were treated with antihypertensive medications. Other characteristics and descriptive statistics are summarized by sex in Table 2.
|
|
Interindividual Variation in Volume of Leukoaraiosis
The distribution of the volume of leukoaraiosis was positively skewed, with values ranging from 1.2 to 61.9 cm3 (Figure). Before fitting the subsequent statistical models, which assume that the measure of leukoaraiosis volume is normally distributed, the raw measurements were logarithm-transformed, which reduced the skewness measure from 3.55 to 0.78. A multiple linear regression model that included sex, age, systolic blood pressure, and brain volume accounted for 32.3% of interindividual variation in the logarithm-transformed measure of leukoaraiosis volume (Table 3). Based on the model, older age, systolic blood pressure, and brain volume were each associated with greater volume of leukoaraiosis. Although women tended to have less leukoaraiosis than men (Table 2), sex did not make a significant additional contribution to the prediction of leukoaraiosis volume when other predictors were in the model. None of the other characteristics in Table 2 made a significant contribution to prediction of leukoaraiosis volume when sex, age, systolic blood pressure, and brain volume were in the model; nor did the effects of age, systolic blood pressure, or brain volume differ significantly between sexes. As expected, brain volume and head size were highly correlated (Spearman r=0.87, P<0.0001).
|
|
Heritability of Leukoaraiosis
The point estimate of the heritability (±SE) of the logarithm-transformed measure of leukoaraiosis volume was 0.802 (95% CI: 0.565 to 0.966) (Table 4). Together, the covariates were estimated to account for 31.4% of the interindividual variation in this measure of leukoaraiosis (Table 4), which is close to the estimate from the preceding linear regression model that used a generalized estimating equations approach to control for intrasibship correlations (32.3%) (Table 3). Age and sex accounted for most of the variation attributable to covariates; the additional variation explained by brain volume (or by head size) was <2%. After adjustments for all covariates, the estimated heritability of the logarithm-transformed measure of leukoaraiosis volume was reduced to 0.671 (95% CI: 0.436 to 0.864).
|
| Discussion |
|---|
|
|
|---|
The estimated heritability of leukoaraiosis exceeds estimates for other heritable risk factors for cerebrovascular disease,18 including blood pressure levels and hypertension.19 Consistent with previous clinic and population-based studies, we found that older age and higher systolic blood pressure were associated with greater volume of leukoaraiosis. However, because all subjects had diagnosed hypertension or
2 hypertensive siblings, categorically defined hypertension was not a predictor of leukoaraiosis. Even though most hypertensive subjects were treated with medication, measured systolic blood pressure still made a small contribution to the prediction of leukoaraiosis. The relatively greater predictive effects of age may in part be explained by its indexing the duration of exposure to hypertension. Because measures of plasma lipids, smoking, and glucose intolerance were not predictive of leukoaraiosis, we may infer that most additive genetic factors contributing to leukoaraiosis act via novel pathways not reflected in known risk factors for atherosclerotic cerebrovascular disease.
The high estimated heritability of leukoaraiosis among siblings of both sexes is close to a previous estimate in older male twins.8 This suggests the finding is robust to differences in family sampling design and sex. Unfortunately, the numbers of malemale sibling pairs (n=64) and femalefemale sibling pairs (n=169) were too small to formally assess the possibility of gender differences in the heritability of leukoaraiosis. Because our subjects had hypertension or were from families with a high prevalence of hypertension, they may have more leukoaraiosis than age- and sex-matched individuals from the general population. Even though we controlled for differences in measured blood pressure, it is still possible that the heritability estimates of leukoaraiosis volume may be inflated. Moreover, the present sample only included non-Hispanic white individuals. Because black individuals have more hypertension and greater susceptibility to microvascular complications,20,21 extension of this investigation to samples including black subjects is indicated.
Because our analysis did not estimate shared environments, a further caveat regarding the heritability estimates is that the genetic contribution may be overestimated. Although the siblings were on average 65 years old and all lived in separate households, it is possible that environments shared early in life contribute to familial aggregation of leukoaraiosis volume. Study of second-degree relatives and spouses could help resolve this question. Whereas environmental rather than genetic factors are typically viewed as relatively more important in the pathogenesis of conditions that develop late in life, the reverse appears to be true for measures of cognitive ability, the heritability of which increases from childhood to adulthood and old age.22 Possible age-dependence of leukoaraiosis heritability remains to be determined. Associations between cognitive measures and brain structure and regional differences in the magnitude of genetic influence on brain morphology has supported the possibility of familial susceptibility to degenerative diseases, particularly those affecting highly genetically determined regions of the brain.6
Studies attempting to relate measured genetic variation to interindividual differences in leukoaraiosis are few, but there appear to be many genes that are plausible candidates to contribute to subcortical white matter ischemia and the development of leukoaraiosis. Genetic variants that influence levels of established intermediate risk factors, particularly hypertension, have been the subject of most investigations. Associations have been reported with polymorphisms in the genes encoding angiotensinogen,23 angiotensin-converting enzyme,24 paraoxonase PON1,25 apolipoprotein(a), and methylene tetrahydrofolate reductase.26 Associations with variants in the gene encoding apolipoprotein E have been inconsistent.27,28 The substantial heritability of leukoaraiosis, even after adjustment for the identified covariates, suggests that there are likely to be numerous other genetic pathways besides those acting through known risk factors for cerebrovascular disease. Although there are no reports of genome-wide scans yet, such an undertaking may reveal previously unsuspected mechanisms acting through novel pathways.
Perspectives
Efforts are underway to identify and characterize the genetic determinants of hypertension and its cardiac and renal complications.9 Likewise, the genetic architecture of brain morphology and function and their responses to aging continue to be areas of intense investigation. As mortality caused by atherosclerotic complications decreases, target organ complications of ischemia caused by arteriolosclerosis are bound to increase with aging of the population. The combined application of high-resolution, noninvasive imaging and genomic technologies promises to advance understanding of the pathogenesis of leukoaraiosis and provide for better detection, evaluation, treatment, and prevention of this emerging risk factor for dementia.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received September 30, 2003; first decision October 27, 2003; accepted November 26, 2003.
| References |
|---|
|
|
|---|
2. Hachinski VC, Potter P, Merskey H. Leuko-araiosis: an ancient term for a new problem. Can J Neurol Sci. 1986; 13: 533534.[Medline] [Order article via Infotrieve]
3. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. JAMA. 1995; 274: 18461851.
4. Sing C, Haviland M, Reilly S. Genetic architecture of common multifactorial diseases. In: Chadwick D, Cardew G, eds. Variation in the Human Genome. Chichester: John Wiley and Sons; 1996: 211232.
5. Turner ST, Boerwinkle E. Genetics of hypertension, target-organ complications, and response to therapy. Circulation. 2000; 102: IV40IV45.[Medline] [Order article via Infotrieve]
6. Thompson PM, Cannon TD, Narr KL, van Erp T, Poutanen VP, Huttunen M, Lonnqvist J, Standertskjold-Nordenstam CG, Kaprio J, Khaledy M, Dail R, Zoumalan CI, Toga AW. Genetic influences on brain structure. Nature Neurosci. 2001; 4: 12531258.[CrossRef][Medline] [Order article via Infotrieve]
7. Pfefferbaum A, Sullivan EV, Swan GE, Carmelli D. Brain structure in men remains highly heritable in the seventh and eighth decades of life. Neurobiol Aging. 2000; 21: 6374.[Medline] [Order article via Infotrieve]
8. Carmelli D, DeCarli C, Swan GE, Jack LM, Reed T, Wolf PA, Miller BL. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke. 1998; 29: 11771181.
9. Multi-center genetic study of hypertension: The Family Blood Pressure Program (FBPP). Hypertension. 2002; 39: 39.
10. Jack CR, Jr., Twomey CK, Zinsmeister AR, Sharbrough FW, Petersen RC, Cascino GD. Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults. Radiology. 1989; 172: 549554.
11. Rydberg JN, Riederer SJ, Rydberg CH, Jack CR. Contrast optimization of fluid-attenuated inversion recovery (FLAIR) imaging. Magnetic Resonance Med. 1995; 34: 868877.
12. Jack CR, Jr, OBrien PC, Rettman DW, Shiung MM, Xu Y, Muthupillai R, Manduca A, Avula R, Erickson BJ. FLAIR histogram segmentation for measurement of leukoaraiosis volume. J MRI. 2001; 14: 668676.
13. Pere A. Comparison of two methods for transforming height and weight to normality. Ann Hum Biol. 2000; 27: 3545.[CrossRef][Medline] [Order article via Infotrieve]
14. Breiman L. Classification and regression trees. Belmont, CA: Wadsworth International Group; 1984.
15. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986; 42: 121130.[CrossRef][Medline] [Order article via Infotrieve]
16. Lange K, Westlake J, Spence MA. Extensions to pedigree analysis. III. Variance components by the scoring method. Ann Hum Genet. 1976; 39: 485491.[Medline] [Order article via Infotrieve]
17. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet. 1998; 62: 11981211.[CrossRef][Medline] [Order article via Infotrieve]
18. Fox CS, Polak JF, Chazaro I, Cupples A, Wolf PA, DAgostino RA, ODonnell CJ, Framingham Heart S. Genetic and environmental contributions to atherosclerosis phenotypes in men and women: heritability of carotid intima-media thickness in the Framingham Heart Study. Stroke. 2003; 34: 397401.
19. Ward R. Familial aggregation and genetic epidemiology of blood pressure. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press; 1995: 6788.
20. Liao D, Cooper L, Cai J, Toole J, Bryan N, Burke G, Shahar E, Nieto J, Mosley T, Heiss G. The prevalence and severity of white matter lesions, their relationship with age, ethnicity, gender, and cardiovascular disease risk factors: the ARIC study. Neuroepidemiology. 1997; 16: 149162.[Medline] [Order article via Infotrieve]
21. Freedman BI. Renal microvascular susceptibility in African Am pedigrees. Transplant Proc. 1993; 25: 24232425.[Medline] [Order article via Infotrieve]
22. McClearn GE. Substantial genetic influence on cognitive abilities in twins 80 or more years old. Science. 1997; 276: 15601563.
23. Schmidt R, Schmidt H, Fazekas F, Launer LJ, Niederkorn K, Kapeller P, Lechner A, Kostner GM. Angiotensinogen polymorphism M235T, carotid atherosclerosis, and small- vessel disease-related cerebral abnormalities. Hypertension. 2001; 38: 110115.
24. Sierra C. Cerebral white matter lesions in essential hypertension. Curr Hypertens Rep. 2001; 3: 429433.[Medline] [Order article via Infotrieve]
25. Schmidt R, Schmidt H, Fazekas F, Kapeller P, Roob G, Lechner A, Kostner GM, Hartung HP. MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms: three-year follow-up of the Austrian stroke prevention study. Arterioscler Thromb Vasc Biol. 2000; 20: 18111816.
26. Notsu Y, Nabika T, Park H, Masuda J, Kobayashi S. Evaluation of genetic risk factors for silent brain infarction. Stroke. 1999; 30: 18811886.
27. Schmidt R, Schmidt H, Fazekas F, Schumacher M, Niederkorn K, Kapeller P, Weinrauch V, Kostner GM. Apolipoprotein E polymorphism and silent microangiopathy-related cerebral damage. Results of the Austrian Stroke Prevention Study. Stroke. 1997; 28: 951956.
28. Kuller LH, Shemanski L, Manolio T, Haan M, Fried L, Bryan N, Burke GL, Tracy R, Bhadelia R. Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study. Stroke. 1998; 29: 388398.
This article has been cited by other articles:
![]() |
L. Paternoster, W. Chen, and C. L.M. Sudlow Genetic Determinants of White Matter Hyperintensities on Brain Scans: A Systematic Assessment of 19 Candidate Gene Polymorphisms in 46 Studies in 19 000 Subjects * Supplemental References Stroke, June 1, 2009; 40(6): 2020 - 2026. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Arsava, R. Rahman, J. Rosand, J. Lu, E. E. Smith, N. S. Rost, A. B. Singhal, M. H. Lev, K. L. Furie, W. J. Koroshetz, et al. Severity of leukoaraiosis correlates with clinical outcome after ischemic stroke Neurology, April 21, 2009; 72(16): 1403 - 1410. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Eckman, L. K.S. Wong, Y. O.Y. Soo, W. Lam, S. R. Yang, S. M. Greenberg, and J. Rosand Patient-Specific Decision-Making for Warfarin Therapy in Nonvalvular Atrial Fibrillation: How Will Screening With Genetics and Imaging Help? * Supplemental Appendix Stroke, December 1, 2008; 39(12): 3308 - 3315. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Altaf, P. S. Morgan, A. Moody, S. T. MacSweeney, J. R. Gladman, and D. P. Auer Brain White Matter Hyperintensities Are Associated with Carotid Intraplaque Hemorrhage Radiology, July 1, 2008; 248(1): 202 - 209. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. S. Rost, S. M. Greenberg, and J. Rosand The Genetic Architecture of Intracerebral Hemorrhage Stroke, July 1, 2008; 39(7): 2166 - 2173. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ay, E. M. Arsava, J. Rosand, K. L. Furie, A. B. Singhal, P. W. Schaefer, O. Wu, R. G. Gonzalez, W. J. Koroshetz, and A. G. Sorensen Severity of Leukoaraiosis and Susceptibility to Infarct Growth in Acute Stroke Stroke, May 1, 2008; 39(5): 1409 - 1413. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. V. Bowler Modern concept of vascular cognitive impairment Br. Med. Bull., September 1, 2007; 83(1): 291 - 305. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Dichgans and R. A. Hegele Update on the Genetics of Stroke and Cerebrovascular Disease 2006 Stroke, February 1, 2007; 38(2): 216 - 218. [Full Text] [PDF] |
||||
![]() |
J. V. Bowler and P. B. Gorelick Advances in Vascular Cognitive Impairment 2006 Stroke, February 1, 2007; 38(2): 241 - 244. [Full Text] [PDF] |
||||
![]() |
C. Opherk, N. Peters, M. Holtmannspotter, A. Gschwendtner, B. Muller-Myhsok, and M. Dichgans Heritability of MRI Lesion Volume in CADASIL: Evidence for Genetic Modifiers Stroke, November 1, 2006; 37(11): 2684 - 2689. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. DeStefano, L. D. Atwood, J. M. Massaro, N. Heard-Costa, A. Beiser, R. Au, P. A. Wolf, and C. DeCarli Genome-Wide Scan for White Matter Hyperintensity: The Framingham Heart Study Stroke, January 1, 2006; 37(1): 77 - 81. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G. Leblanc, J. F. Meschia, D. T. Stuss, and V. Hachinski Genetics of Vascular Cognitive Impairment: The Opportunity and the Challenges Stroke, January 1, 2006; 37(1): 248 - 255. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H.G. Henskens, A. A. Kroon, M. P.J. van Boxtel, P. A.M. Hofman, and P. W. de Leeuw Associations of the Angiotensin II Type 1 Receptor A1166C and the Endothelial NO Synthase G894T Gene Polymorphisms With Silent Subcortical White Matter Lesions in Essential Hypertension Stroke, September 1, 2005; 36(9): 1869 - 1873. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Hill and J. D. Bisognano Leukoaraiosis: The brain under pressure: Target for treatment? Neurology, June 14, 2005; 64(11): 1832 - 1833. [Full Text] [PDF] |
||||
![]() |
S. T. Turner, M. Fornage, C. R. Jack Jr, T. H. Mosley, S. L. R. Kardia, E. Boerwinkle, and M. de Andrade Genomic Susceptibility Loci for Brain Atrophy in Hypertensive Sibships From the GENOA Study Hypertension, April 1, 2005; 45(4): 793 - 798. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. K. Gupta, C. DeCarli, L. D. Atwood, and P. A. Wolf White Matter Hyperintensities: Pearls and Pitfalls in Interpretation of MRI Abnormalities * Response: Stroke, December 1, 2004; 35(12): 2756 - 2757. [Full Text] [PDF] |
||||
![]() |
J. F. Meschia Clinically Translated Ischemic Stroke Genomics Stroke, November 1, 2004; 35(11_suppl_1): 2735 - 2739. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Gwinn-Hardy and V. Dawson Genomics-Proteomics and Stroke: Introduction Stroke, November 1, 2004; 35(11_suppl_1): 2731 - 2734. [Full Text] [PDF] |
||||
![]() |
F. C. Luft Geneticism of Essential Hypertension Hypertension, June 1, 2004; 43(6): 1155 - 1159. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |